Leadership

Jan van de Winkel, Ph.D., became the Executive Director of the Merus Board and Chief Executive Officer in December 2025.

Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. He has more than 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 150 patents and pending patent applications.

Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University and also holds M.S. and Ph.D. degrees from the University of Nijmegen.

He is a registered manager of Genmab with the Danish Business Authority.

Cornelis Adriaan (“John”) de Kruif, Ph.D. has served as our Chief Technology Officer since January 2013 and previously served as our Chief Scientific Officer from April 2007 to January 2013.

His responsibilities include management of antibody discovery, antibody platform technology development, antibody engineering, external collaborations, partnerships management and operational activities. Before joining Merus, from October 2000 to October 2006, he served as a director of antibody discovery for Crucell N.V., a biotechnology company, specializing in vaccines and biopharmaceutical technology. Dr. de Kruif holds a Ph.D., in Antibody Engineering from Utrecht University.

Cecilia (“Cecile”) Anna Wilhelmina Geuijen, Ph.D has served as our Chief Scientific Officer since May 2021.

Her responsibilities include strategic scientific leadership, management of pre-clinical research, external collaborations, partnerships management and operational activities. Before joining Merus in 2009, Dr. Geuijen worked as a senior scientist on the evaluation of new therapeutic targets in oncology at Genmab and the identification of new therapeutic targets in oncology at Crucell. She holds a Ph.D. in Biology from the University of Utrecht and was a Marie Curie Fellow at the Duve Institute in Brussels.

Ernesto Wasserman, M.D. has served our company since December 2016, first as our Vice President of Clinical Development and currently as Senior Vice President of Clinical Development since January 2022.

His responsibilities include overseeing the planning and executing of clinical programs from early stage through to potential registration. He has over 20 years of experience in oncology clinical drug development. Prior to joining Merus, Dr. Wasserman held positions of increasing responsibility at Novartis, leading development of early and late stage small molecules and biologics in oncology. Notably, he played a key role in the execution of a pivotal clinical program in metastatic melanoma leading to regulatory approval of Braftovi and Mektovi, and contributing to the clinical strategy for Novartis™ immuno-oncology portfolio. Dr. Wasserman is a board certified oncologist; he received his M.D. from the University of Buenos Aires, completed a fellowship in medical oncology at Hopital Paul Brousse (Paris) and visiting fellowships at Hospital 12 de Octubre (Madrid), Memorial Sloan Kettering (New York), and the National Cancer Center (Japan).

Anand Mehra, M.D. has served as a non-executive director since August 2015 and as Chairperson of our board of directors effective since June 2020. Dr. Mehra held various positions at Sofinnova Investments (f.k.a. Sofinnova Ventures) from 2007 to January 2020, most recently holding the position of a managing general partner, where he focused on working with entrepreneurs to build drug development companies. He led the firm’s investments in Vicept Therapeutics (acquired by Allergan), Aerie Pharmaceuticals, Inc., Aclaris Therapeutics, Inc. (“Aclaris”), and Spark Therapeutics. Prior to joining Sofinnova, Dr. Mehra worked in J.P. Morgan’s private equity and venture capital group and as a consultant at McKinsey & Company. He currently serves as a member of the board of directors of the publicly held life science company Aclaris. Within the past five years, he also served on the boards of directors of the publicly held life science companies Marinus Pharmaceuticals, Inc., Spark Therapeutics, Inc. and Aerie Pharmaceuticals. Dr. Mehra received a B.A. degree in political philosophy from the University of Virginia and an M.D. degree from Columbia University’s College of Physicians and Surgeons.

Maxine Gowen, Ph.D., has served as a non-­executive director to our board of directors since May 2021. Dr. Gowen was the founding President and Chief Executive Officer of Trevena, Inc. (Trevena), from 2007 to October 2018. Prior to this position, Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of 15 years. As Senior Vice President for the company’s Center of Excellence for Drug Discovery, she developed an innovative new approach to externalizing drug discovery. Dr. Gowen was previously President and Managing Partner at SR One, the venture capital subsidiary of GSK, where she led its investments in and served on the boards of directors of numerous companies. Dr. Gowen also previously served as Vice President, Drug Discovery, Musculoskeletal Diseases at GSK, where she was responsible for drug discovery and early development for osteoporosis, arthritis and metastatic bone disease. Dr. Gowen currently serves on the boards of directors of publicly held life science companies Aclaris and Passage Bio, and served on the boards of directors of publicly held life science companies Akebia Therapeutics (Akebia) and Trevena until May 2021 and Aceragen, Inc., until August 2023. Dr. Gowen holds a B.Sc. in biochemistry from the University of Bristol, U.K., received a Ph.D. in cell biology from the University of Sheffield, U.K., and received an M.B.A. from the Wharton School of the University of Pennsylvania.

Mr. Mueller joined Genmab in July 2025 as Executive Vice President, General Counsel & Chief Legal Officer, responsible for leading and managing the global legal, intellectual property, corporate governance, and global compliance and risk functions.

Before joining Genmab, Mr. Mueller spent more than 20 years at AstraZeneca, living and working in North America, Europe and Asia. For the last 12 years, he was part of the Legal Senior Management Team, holding roles as the Deputy General Counsel, International and then as the Deputy General Counsel, Corporate. Prior to AstraZeneca, Mr. Mueller worked as a corporate transactions lawyer at a large national Canadian law firm.

Mr. Mueller holds a Bachelor of Commerce specialist degree from the University of Toronto and a Law Degree (LLB) from Queen’s University.

Anthony Pagano became a non-executive director on the Merus Board of Directors in December 2025.

Mr. Pagano joined Genmab in 2007, was appointed Senior Vice President in 2011, and became Executive Vice President and Chief Financial Officer effective March 1, 2020. Prior to joining Genmab, Mr. Pagano served as Corporate Controller and Senior Director of Business Planning at NovaDel Pharma, a publicly traded specialty pharmaceutical company. He began his career at KPMG LLP, where he rose to the position of Manager and provided audit and M&A consulting services to clients ranging from start-ups to Fortune 500 companies across a broad range of industries.

He is a Certified Public Accountant and received a B.S. in Accounting from The College of New Jersey, as well as an M.B.A. from the Stern School of Business at New York University.

Mr. Pagano is also a registered manager of Genmab with the Danish Business Authority.

Martine J. van Vugt, Ph.D. became a non-executive director on the Merus board of directors in December 2025

Dr. van Vugt started her professional career at Genmab in 2001 and was appointed Executive Vice President in 2023 and is currently responsible for Corporate Strategy, Corporate Development, Business Development and Licensing and Alliance Management. She has been active in business development operations since 2011.

From 1998 until joining Genmab in 2001 she studied dendritic cell vaccination therapy as a post-doctoral fellow. Dr. van Vugt holds an M.S. from the University of Wageningen and a Ph.D. from Utrecht University.

Jan van de Winkel, Ph.D., became the Executive Director of the Merus Board and Chief Executive Officer in December 2025.

Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. He has more than 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 150 patents and pending patent applications.

Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University and also holds M.S. and Ph.D. degrees from the University of Nijmegen.

He is a registered manager of Genmab with the Danish Business Authority.